Opus Genetics reports positive pediatric data from LCA5 gene therapy study
Opus Genetics, Inc. released positive data from a pediatric cohort in an ongoing phase 1/2 clinical study evaluating OPGx-LCA5, an...
Opus
Opus Genetics Announces Presentation of OPGX-LCA5 Gene
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe...
Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease
(Image Credit: AdobeStock/Artinun)Opus Genetics announced the 1-month open-label phase 1/2 results from the first pediatric patients treated with its investigational...
Opus Genetics Announces Presentations at Association for
Durham, NC., March 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene...
Department of Health – Abu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases
ABU DHABI, UAE, June 4, 2024 /PRNewswire/ -- During the BIO 2024 International Convention, the Department of Health – Abu...
Department of Health – Abu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases
ABU DHABI, UAE, June 5, 2024 /PRNewswire/ -- During the BIO 2024 International Convention, the Department of Health – Abu...
Department of Health – Abu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases
Department of Health - Abu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal...
